Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases
NEW YORK and LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Akari…
Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
NEW YORK and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Akari…
Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform
SAN DIEGO, U.S.A., and FREISING, Germany, 18th December, 2018:…